Atlas Trials

A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

Clinical trial NCT06175494 · UNKNOWN

Trial details

NCT number
NCT06175494
Sponsor
WestVac Biopharma Co., Ltd.
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
COVID-19
Start date
2023-12-19
Primary completion
2024-07-31
Enrollment
4800

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.